H35.173
Retrolental fibroplasia, bilateral
Clinical Classification Guidelines
Medical Intelligence & Overview
Retrolental fibroplasia (RLF), also known as retinopathy of prematurity (ROP), is a condition that affects the developing blood vessels of the retina in premature infants. When it occurs in both eyes, it is referred to as bilateral retrolental fibroplasia. This condition can potentially lead to vision impairment or blindness if not diagnosed and managed promptly. Understanding the causes, symptoms, diagnosis, and treatment options is important for caregivers and healthcare professionals caring for at-risk infants.
Causes & Symptoms
Clinical Causes: Premature birth: The primary cause is birth before the complete development of retinal blood vessels. Low birth weight: Infants with very low birth weights are more susceptible due to underdeveloped retinas. Oxygen therapy: Excessive oxygen supplementation during neonatal care can interfere with normal blood vessel development in the retina. Genetic factors: Some genetic predispositions may influence the likelihood of developing ROP. Environmental factors: Conditions such as fluctuating oxygen levels and overall neonatal health can contribute to the development of bilateral RLF.
Key Symptoms: No noticeable symptoms in mild cases, with the condition being often identified during routine eye examinations. Abnormal blood vessel growth in the retina can sometimes cause: Vitreous haze or hemorrhages visible during eye exams Leukocoria, or a white reflection in the pupil (which may appear as a white or grayish patch in the eye) Strabismus, or misalignment of the eyes Decreased visual response or tracking abilities in infants Larger or irregularly shaped pupils
Diagnostic & Treatment
Diagnosis Path: Retinal examination with indirect ophthalmoscopy to evaluate abnormal blood vessel growth Retinal imaging techniques, such as wide-field retinal imaging, to document retinal changes Assessment of the infant’s birth history, oxygen therapy records, and overall health status Regular screening for premature infants, especially those born before 31 weeks gestation or with low birth weight, as per neonatal care guidelines
Treatment Protocols: Laser therapy: Using laser beams to ablate abnormal blood vessels and prevent further growth and bleeding Cryotherapy: Applying freezing treatment to the peripheral retina in more severe cases Anti-VEGF injections: Administering medications that inhibit vascular endothelial growth factor to reduce abnormal vessel growth Monitoring and follow-up: Regular eye examinations to track disease progression and response to treatments Management of underlying health issues: Ensuring optimal oxygen levels and overall neonatal care to minimize further risks
Clinical Advice & FAQs
Billing Guidance
Is H35.173 a billable ICD-10 code?
Yes, H35.173 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report H35.173?
Clinical documentation must specify the nature of Retrolental fibroplasia, bilateral and any associated comorbidities for accurate reporting.
Cite this Clinical Reference